Publications

Journal of Clinical Microbiology, 52(5), 1 May 2014, pp 1741-44, doi: 10.1128/JCM.03614-13
Intensive Care Medicine, 40(4), 1 April 2014, pp 564–571, doi: 10.1007/s00134-014-3225-8
Expert Opinion on Therapeutic Targets, 18(8), 1 August 2014, pp 851-61, doi: 10.1517/14728222.2014.925881

Project Partners

R-GNOSIS is coordinated by Marc Bonten (UMC Utrecht) and brings together a multidisciplinary team with complementary expertise of clinicians, microbiologists and epidemiologists, infectious disease specialists, caregivers in inpatient care and mathematical modellers. The R-GNOSIS consortium is made of 19 partners from 9 countries which include United Kingdom, Denmark, Germany, Netherlands, Belgium, France, Spain, Switzerland and Israel.

University of Antwerp, UA, BE

University of Antwerp, UA, BE


Organizational Activities

The University of Antwerp (UA) has about 13.000 students, which makes it the third largest university in Flanders. In research UA ranks among Europe’s leading universities in terms of relative scientific impact scores in the natural and biomedical sciences (EU Science and Technology Indicators for 2003). The Laboratory of Medical Microbiology (LMM) is part of the Vaccine & Infectious Disease Institute at UA and has an international reputation in investigating the impact of antibiotic use and emergence of antimicrobial resistance both at the ecologic and individual level, the latter by utilizing state-of-the-art molecular techniques as well as developing molecular diagnostic tests for clinical applications. LMM is currently part of two FP6 and four FP7 projects that aim to design, develop and validate point-of-care diagnostic tests for lower respiratory tract infections (GRACE: also coordinator, and TheraEdge) and sepsis (IntOpSens), and study antibiotic resistance mechanisms and the impact of antibiotic therapy on the human commensal flora (MOSAR, GRACE, APRES, and SATURN). As part of nationally funded projects, LMM is investigating the role of virulence factors in biofilm formation and utilizing metagenomic approaches to study antibiotic resistance.  The laboratory is fully equipped in terms of space and laboratory equipment to perform both conventional bacteriological cultures, gel-based and real-time molecular techniques. The laboratory also has full access to microscopy and sequencing support within UA core facilities.

Role in the Project

Key Personnel

Herman Goossens is the head of the Laboratory of Microbiology both at UA (LMM) and the University Hospital, and director of the Vaccine and Infectious Disease Institute. He is an authority on antibiotic use, resistance and molecular diagnostics and has published his research in over 250 full papers in peer-reviewed scientific journals, written 17 chapters in textbooks and presented his research in more than 350 lectures. He holds several expert positions at the Belgian government, European Commission, World Health Organisation, Food and Drug Administration and Centers for Disease Control of the USA. He is the co-ordinator of several European projects, including the European Surveillance of Antibiotic Consumption (ESAC, DG SANCO, 2001-2007, ECDC, 2007-2011), the Biosafety Evaluation of Probiotic Lactic Acid Bacteria Used for Human Consumption (PROSAFE, DG Research, 2002-2005) and the Genomics to combat Resistance against Antibiotics in Community-acquired LRTI in Europe (GRACE, DG Research, 2006-2011) and participates in several other EC projects.

- no image description is available - 

Surbhi Malhotra-Kumar is a clinical and molecular microbiologist, actively involved along with industry and SMEs, in the development of high-throughput and point-of-care diagnostic assays for hospital and community pathogens (MOSAR, TheraEdge, and Intopsens). Using state-of-the-art molecular techniques, she is studying the impact of antibiotic use at the individual level (SATURN) and the role of virulence factors in biofilm formation (national funding).

 - no image description is available -

Christine Lammens, BSc, is a senior technician who conducts research in the field of microbiology, molecular biology and bacterial genetics. She was developing laboratory protocols for clinical trials taken place in GRACE, MOSAR, and SATURN.   

 - no image description is available -

Julia Sabirova is a microbiologist and molecular biologist by training with considerable experience in bacterial genetics and genomics (cloning, transposon mutagenesis, proteomics, genome annotation). Apart from being involved in RGnosis, she is also participating in the work related to establishing next generation sequencing and bioinformatics platforms for S. aureus and K. pneumoniae clinical isolates (national funding).

 - no image description is available -